

Rev05
Update: Aug,31,2026

DATASHEET

MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit

Cat. No.: A02322

Overview

Specificity	This product is specific for Risankizumab.
Host Species	Rabbit
Immunogen	Risankizumab
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Application	Recommended Usage
Sandwich ELISA	0.5-2 µg/ml
ELISA	0.01-1 µg/ml
Competitive ELISA	1-10 µg/ml


Properties

Form	Lyophilized
Storage Buffer	Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable for 1 year at -20°C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8°C or for 12 months at -20°C or below. Avoid repeated freezing and thawing cycles.
Purification	Protein A affinity column

Isotype	Rabbit IgG, κ
Clonality	Monoclonal
Clone ID	32A12
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples


Anti-Risankizumab Antibody (32A12) inhibits the binding of Risankizumab to Human IL23A



Anti-Risankizumab Antibody (32A12) inhibits the binding of Risankizumab to IL-23.

Human IL23A Protein was coated at a concentration of 1 $\mu\text{g/mL}$, followed by the addition of Risankizumab at 0.6 $\mu\text{g/mL}$ and Anti-Risankizumab antibody that was serially diluted starting from 10 $\mu\text{g/mL}$. Detection was performed using Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) diluted at 1:10,000. MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit (GenScript, A02322) demonstrated inhibitory properties with an IC_{50} value of 0.18 $\mu\text{g/mL}$.


Binding affinity measurements of MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit to Risankizumab



BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit (GenScript, A02322) to Risankizumab.

Risankizumab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit with a dissociation constant (K_D) of less than 1 pM.

MRD Analysis of the Detection of Risankizumab in Biological Matrix




MRD Analysis of the Detection of Risankizumab in Biological Matrix.

The MRD is the minimum dilution necessary for the detection of Risankizumab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:10.

In this ELISA assay, MonoRab™ Anti-Risankizumab Antibody (3A11), mAb, Rabbit (GenScript, A02321) was coated at a concentration of 1 $\mu\text{g/mL}$, and MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit (GenScript, A02322) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 $\mu\text{g/mL}$.


Specificity analysis of the detection of Risankizumab



Specificity analysis of the detection of Risankizumab.

Risankizumab standard samples at 6 concentrations were spiked with 10 µg/mL of human IgG1. The test result demonstrated that the high concentration of human IgG1 did not interfere with the detection of Risankizumab. In this ELISA assay, MonoRab™ Anti-Risankizumab Antibody (3A11), mAb, Rabbit (GenScript, A02321) was coated at a concentration of 1 µg/mL, and MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit (GenScript, A02322) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 µg/mL.

Standard Curve of Risankizumab Sandwich ELISA by A02321 (3A11) and A02322 (32A12)




Standard Curve of Risankizumab Sandwich ELISA by A02321 (3A11) and A02322 (32A12).

In this Sandwich ELISA assay, MonoRab™ Anti-Risankizumab Antibody (3A11), mAb, Rabbit (GenScript, A02321) was coated at a concentration of 1 µg/mL, and MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit (GenScript, A02322) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 µg/mL. GenScript can provide customized conjugation service for this product per customer's request.

In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99957. The typical dynamic range of the assay is 0.078 - 2.5 ng/mL.

Standard Curve of Risankizumab Sandwich ELISA by A02322 (32A12) and anti-human IgG Fc antibody



Standard Curve of Risankizumab Sandwich ELISA by A02322 (32A12) and anti-human IgG Fc antibody.

In this Sandwich ELISA assay, MonoRab™ Anti-Risankizumab Antibody (32A12), mAb, Rabbit (GenScript, A02322) was coated at a concentration of 1 µg/mL, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) was used as a detection antibody at a dilution of 1:10,000.

In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99999. The typical dynamic range of the assay is 0.14 - 11 ng/mL.

Background

Target Background : Risankizumab is a monoclonal antibody designed to target interleukin-23 (IL-23), a key cytokine involved in the inflammatory process of certain autoimmune diseases. By specifically binding to the p19 subunit of IL-23, Risankizumab inhibits its interaction with the IL-23 receptor, thereby reducing inflammation and immune responses. This mechanism makes Risankizumab particularly effective in the treatment of moderate to severe plaque psoriasis. The drug is marketed under the brand name Skyrizi and has shown superior efficacy compared to other biologics in its class. It is also being studied for potential use in other inflammatory conditions, such as Crohn's disease.

Synonyms : Risankizumab; risankizumab-rzaa; Skyrizi; ABBV-066; BI-655066; BI 655066

Limited Use License and Use Restrictions

Limited Use License and Use Restrictions

This Product is provided under a limited, non-exclusive, non-transferable, and non-sublicensable end-user license strictly limited to the permitted uses set forth in GenScript's official documentation, quotations, or written agreements. Any use beyond such scope requires GenScript's prior written authorization or license.

Except as expressly authorized in writing by GenScript, Customer shall not, and shall not permit, procure, enable, or assist any third party to: (a) commercialize or otherwise exploit the Product, including by reselling, distributing, transferring, sublicensing, or otherwise making the Product (including any product incorporating the Product) available to any third party; (b) copy, reproduce, clone, reverse clone, sequence, analyze, characterize, deconstruct, reconstruct, reverse engineer, or otherwise attempt to discover the composition, sequence, structure, binding characteristics, epitope recognition characteristics, or other proprietary features of the Product; (c) modify, derivatize, humanize, optimize, mutate, design around, or generate any variants, derivatives, fragments, substitutes, or functional equivalents of the Product; or (d) use the Product, any information derived therefrom, or any computational, AI-enabled, or sequence-based design method to develop, manufacture, offer for sale, sell, or commercialize any product or service competitive with the Product or GenScript's products or services.

All intellectual property rights and all rights not expressly granted herein are reserved by GenScript. No rights are granted by implication, estoppel, or otherwise.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China